BOTUSA, the CDC collaboration with the government of Botswana, is conducting a Phase III randomized, placebo controlled trial of the safety and efficacy of a single daily oral dose of the antiretroviral (ARV) Truvada for the prevention of HIV infection among 1200 sexually active young adults in Botswana (henceforth referred to as TDF2 trial). Such trials are commonly referred to oral chemoprophylaxis or pre-exposure prophylaxis trials (PrEP).

The purpose of this project is to systematically identify general community and key stakeholders' (HIV positive persons, clinicians who care for HIV positive persons) attitudes, knowledge, concerns, and potential misconceptions about a Phase II/III randomized, placebo controlled trial of the safety and efficacy of a single daily oral dose of the antiretroviral Truvada for the prevention of HIV infection currently being conducted among sexually active young adults in Botswana. Specifically, the contractor, in conjunction with CDC, will conduct a multi-wave, longitudinal community based research study employing administration and data-entry of survey and qualitative key informant interviews. This study will be conducted throughout the life of the TDF2 trial, including active enrollment, follow-up, data analysis, announcement of trial results, and for 3-6 months after the announcement of the results. This end date for this is anticipated to be late 2010.